Swedbank AB Has $157.02 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Swedbank AB lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 10.1% during the third quarter, Holdings Channel.com reports. The fund owned 149,363 shares of the biopharmaceutical company’s stock after buying an additional 13,705 shares during the period. Swedbank AB’s holdings in Regeneron Pharmaceuticals were worth $157,016,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of REGN. International Assets Investment Management LLC increased its position in Regeneron Pharmaceuticals by 86,013.3% during the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock worth $926,078,000 after buying an additional 879,916 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in Regeneron Pharmaceuticals by 1.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company’s stock worth $707,759,000 after buying an additional 11,499 shares during the last quarter. Massachusetts Financial Services Co. MA increased its position in Regeneron Pharmaceuticals by 12.4% during the second quarter. Massachusetts Financial Services Co. MA now owns 540,293 shares of the biopharmaceutical company’s stock worth $567,864,000 after buying an additional 59,769 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in Regeneron Pharmaceuticals by 23.8% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,274 shares of the biopharmaceutical company’s stock worth $525,804,000 after buying an additional 96,266 shares during the last quarter. Finally, TD Asset Management Inc increased its position in Regeneron Pharmaceuticals by 30.4% during the second quarter. TD Asset Management Inc now owns 351,545 shares of the biopharmaceutical company’s stock worth $369,484,000 after buying an additional 82,034 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. Royal Bank of Canada reduced their price objective on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a report on Friday, November 1st. Oppenheimer reduced their price objective on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. JPMorgan Chase & Co. reduced their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a report on Thursday, October 24th. Morgan Stanley reduced their price objective on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Finally, Leerink Partners restated a “market perform” rating and set a $1,077.00 price objective (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $1,099.55.

Regeneron Pharmaceuticals Stock Down 0.9 %

NASDAQ REGN opened at $738.00 on Friday. The business has a fifty day moving average price of $945.07 and a two-hundred day moving average price of $1,027.02. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $735.95 and a fifty-two week high of $1,211.20. The stock has a market capitalization of $81.10 billion, a PE ratio of 18.26, a PEG ratio of 2.87 and a beta of 0.15.

Insider Transactions at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. This represents a 27.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.